No­vo Nordisk gets PhI­II he­mo­phil­ia tri­als for a Roche ri­val back on track af­ter com­plet­ing work-around on blood clot threat

Af­ter abrupt­ly shut­ting down three he­mo­phil­ia stud­ies back in March due to se­ri­ous safe­ty is­sues, No­vo Nordisk is get­ting things go­ing again.

The Dan­ish phar­ma gave the go-ahead to re­sume Phase III tri­als for its con­cizum­ab can­di­date, which are in­ves­ti­gat­ing sub­cu­ta­neous pro­phy­lax­is treat­ment in he­mo­phil­ia A and B pa­tients re­gard­less of in­hibitor sta­tus. No­vo Nordisk had halt­ed the stud­ies af­ter three pa­tients ex­pe­ri­enced non-fa­tal blood clots.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.